pyrroles has been researched along with Erythremia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Rahman, I; Murphy, C | 1 |
| Apostolidou, E; Borthakur, G; Burger, I; Kantarjian, H; Thomas, D; Verstovsek, S | 1 |
| Cortes, JE; Estrov, Z; Gaikwad, A; Kantarjian, HM; Manshouri, T; Nussenzveig, RH; Prchal, J; Quintás-Cardama, A; Verstovsek, S | 1 |
1 trial(s) available for pyrroles and Erythremia
| Article | Year |
|---|---|
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Pyrroles; Sunitinib; Thrombocythemia, Essential | 2010 |
2 other study(ies) available for pyrroles and Erythremia
| Article | Year |
|---|---|
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Polycythemia Vera; Pyrroles; Recurrence; Stroke; Treatment Outcome | 2015 |
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Topics: Animals; Apoptosis; Blotting, Western; Bone Marrow; Cell Cycle; Cell Nucleus; Cell Proliferation; Cells, Cultured; Erythroid Precursor Cells; Erythropoietin; Flow Cytometry; Humans; Immunoprecipitation; Janus Kinase 2; Membrane Potential, Mitochondrial; Mice; Mutation; Phosphorylation; Piperidines; Polycythemia Vera; Protein Kinase Inhibitors; Protein Transport; Pyrimidines; Pyrroles; Receptors, Erythropoietin; Signal Transduction; STAT3 Transcription Factor | 2008 |